Portage Biotech Stock Today
| PRTG Stock | USD 4.72 0.10 2.16% |
Performance2 of 100
| Odds Of DistressOver 81
|
Portage Biotech is trading at 4.72 as of the 26th of November 2024. This is a 2.16 percent increase since the beginning of the trading day. The stock's lowest day price was 4.37. Portage Biotech has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Portage Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of January 2024 and ending today, the 26th of November 2024. Click here to learn more.
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. It also provides Nanolipogel co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company has 1.05 M outstanding shares of which 14.52 K shares are at this time shorted by private and institutional investors with about 0.16 trading days to cover. More on Portage Biotech
Moving against Portage Stock
Portage Stock Highlights
Portage Biotech (PRTG) is traded on NASDAQ Exchange in USA. It is located in Clarence Thomas Building, Tortola, British Virgin Islands, VG1110 and employs 7 people. Portage Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.85 M. Portage Biotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.05 M outstanding shares of which 14.52 K shares are at this time shorted by private and institutional investors with about 0.16 trading days to cover.
Portage Biotech currently holds about 21.18 M in cash with (14.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.25.
Check Portage Biotech Probability Of Bankruptcy
Ownership AllocationPortage Biotech has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Portage Ownership Details
Portage Biotech Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Portage Biotech market risk premium is the additional return an investor will receive from holding Portage Biotech long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0338 | |||
| Jensen Alpha | 0.7028 | |||
| Total Risk Alpha | (2.20) | |||
| Sortino Ratio | 0.0397 |
Portage Stock Against Markets
Portage Biotech Corporate Management
| MD MBA | CEO Board | Profile | |
| Allan CPA | Chief Officer | Profile | |
| Adam Melero | Controller | Profile | |
| EunJae CPA | Chief Officer | Profile | |
| Robert Kramer | Chief Officer | Profile | |
| Brian Wiley | Chief Officer | Profile | |
| Andrea Park | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.